View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
June 1, 2018

Daiichi Sankyo doses first patient in Phase ll trial of DS-8201

Daiichi Sankyo Company has dosed the first patient in a Phase ll trial evaluating the efficacy and safety of DS-8201 for the treatment of patients with unresectable and/or metastatic non-squamous HER2-overexpressing or HER2-mutated non-small cell lung cancer (NSCLC) that has progressed after one or more prior therapies.

Daiichi Sankyo Company has dosed the first patient in a Phase ll trial evaluating the efficacy and safety of DS-8201 for the treatment of patients with unresectable and/or metastatic non-squamous HER2-overexpressing or HER2-mutated non-small cell lung cancer (NSCLC) that has progressed after one or more prior therapies.

The global, multicentre, open-label, two-cohort trial includes two cohorts, one and two.

The cohort one will enrol nearly 40 patients with HER2-overexpressing (defined as IHC 3+ or IHC 2+), unresectable and/or metastatic non-squamous NSCLC, while the cohort two will include about 40 patients with HER2-mutated, unresectable and/or metastatic non-squamous NSCLC.

The trial’s primary endpoint is to achieve an objective response rate.

Its key secondary endpoints are efficacy, safety, and pharmacokinetic endpoints. Exploratory efficacy endpoints of the trial include time to respond, in addition to biomarker endpoints for mechanisms of response and resistance.

“There is renewed interest in exploring alterations in the HER2 pathway as treatment targets for NSCLC and clinical research suggests a potential role for a HER2-targeting ADC agent.”

Around 80 patients are scheduled to be enrolled in the trial at 20 sites in North America, Japan, and Europe.

Daiichi Sankyo Oncology Research and Development Global Team Leader DS-8201 vice-president Gilles Gallant said: “There is renewed interest in exploring alterations in the HER2 pathway as treatment targets for NSCLC and clinical research suggests a potential role for a HER2-targeting ADC agent.

“DS-8201 is specifically designed to target and deliver chemotherapy inside HER2-expressing cancer cells, and we are advancing it to Phase ll in non-small cell lung cancer as part of our broad programme in multiple types of HER2-expressing tumours.”

According to World Health Organization’s Cancer Fact Sheet 2017 and other research, lung cancer is estimated to be the most common cancer in the world and the major cause of cancer deaths.

They have also estimated that about 1.8 million new cases of lung cancer were reported globally in 2012 and nearly 1.69 million deaths occurred globally due to lung cancer in 2015.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU